Fewer uncertain results. Superior diagnostic yields. Increasing insurance coverage. Supported by medical guidelines. The time for exome is now.
An estimated 44% of patients with neurological disorders will receive a delayed or incorrect diagnosis1, and patients with rare neurodevelopmental disorders wait over 6 years on average for a diagnosis.2
But it doesn’t have to be this way for your patients.
Whole exome sequencing (WES) is a comprehensive, cost-effective option that is recommended for patients with conditions such as unexplained epilepsy, cerebral palsy, autism spectrum disorder, intellectual disabilities, congenital anomalies, and developmental delays.3-6
For patients with unknown or unexplained pediatric conditions, exome testing can significantly reduce the time to diagnosis – sometimes by more than six years – sparing your patients years of missed milestones, widened developmental gaps, the strain of uninformative tests, and inefficient treatments.2,3
This is why leading medical societies, including the American College of Medical Genetics and Genomics (ACMG), the National Society of Genetic Counselors (NSGC), and the American Epilepsy Society (AES), recommend exome or genome sequencing as a first-tier test.3,4
Don’t miss us at the Society for Developmental & Behavioral Pediatrics (SDBP) annual conference September 9-11 in Minneapolis! Learn about our research and how GeneDx can deliver higher diagnostic rates and reduce the time to diagnosis.
Insurance coverage is expanding. Over 70% of commercial health plans cover exome sequencing for children with neurodevelopmental disorders that meet clinical criteria.6
For many patients, insurance may provide better coverage for exome than multi-gene panels.6
Flexible billing and payment options. Cost shouldn’t be a barrier to getting critical health information. Our billing experts work with families to access testing so patients can get the care they need. We offer flexible payment plans and offer a Financial Assistance Program for eligible patients.
4 out of 5 GeneDx patients who received exome testing had $0 out-of-pocket responsibility for testing.9
Comprehensive genetic testing like exome sequencing can unlock the potential for more effective treatments and can lead to changes in medical management in up to 30% of cases.5
Help your patients get the care they need earlier.
GeneDx is driven to help make precision medicine the standard of care for your patients. With a team of genetic counselors, MD/PhD scientists, and clinical and molecular diagnostics specialists, we provide the support you need during the genetic testing process to understand ordering, results interpretation, and everything in between. We also provide comprehensive genetic counseling services for your patients from our team of board-certified genetic counselors.
GeneDx offers greater diagnostic accuracy by leveraging our curated dataset of over 500,000 clinical exomes, which enables us to deliver more definitive diagnoses and clinically actionable reports. Every patient sample strengthens our industry-leading interpretation platform, empowering us to deliver diagnoses, even in the most complex cases.
GeneDx was spun out of the National Institutes of Health (NIH) over 20 years ago. We haven’t lost sight of our origins in research either – we regularly contribute scientific findings to the genetics and genomic communities and beyond, further fueling innovation and improved diagnostics for more and more patients.13
With comprehensive care from start to finish, we offer more than just a test result.
Experience the GeneDx difference and help your patients find answers.
References